Several studies have been conducted looking at the prognostic and predictive value of the CD3+ and/or CD8+ cells with or without immunosuppressive cells in the TME in patients with BC; however, none of these studies investigated the ISCR and its clinical utility [19,20,21,22,23,24,25]. This evidence concerns the gene CD8A and breast cancer.